Cryoport And Cell And Gene Therapy Catapult Announce Strategic Collaboration At Stevenage Manufacturing Innovation Centre For Advancement Of Cell And Gene Therapies
Portfolio Pulse from Benzinga Newsdesk
Cryoport, Inc. (NASDAQ:CYRX) and the Cell and Gene Therapy Catapult (CGT Catapult) have announced a strategic partnership to advance cell and gene therapies. Cryoport will establish its first global supply chain logistics center in the U.K., providing the U.K. cell and gene therapy community with access to its integrated supply chain capabilities. The collaboration will commence operations in early 2024.
October 10, 2023 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cryoport's partnership with CGT Catapult to establish a logistics center in the U.K. could potentially expand its global footprint and accelerate the development and commercialization of cell and gene therapies in the U.K.
The partnership with CGT Catapult allows Cryoport to establish its first global supply chain logistics center in the U.K., which is a significant step in expanding its global footprint. This could potentially lead to increased revenues and growth for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100